[Type 2 Charcot-Marie-Tooth disease?].

Area of Science:

• Neurology
• Genetics
• Pathology

Context:

• Type 2 Charcot-Marie-Tooth disease (CMTD-2) affects individuals similarly to CMTD-1, with onset varying from the second to seventh decades.
• Clinical differentiation between CMTD-1 and CMTD-2 is not possible; however, amyotrophia is more pronounced in CMTD-2 for similar muscle weakness.
• Electrophysiological findings in CMTD-2 include normal or minimally slowed nerve conduction velocities (≥38 m/s) and reduced nerve potentials, particularly in lower limbs.

Purpose:

• To highlight the diagnostic challenges in differentiating CMTD-1 from CMTD-2.
• To underscore the limitations of current electrophysiological methods for early and presymptomatic carrier diagnosis.
• To emphasize the need for genetic locus identification for molecular diagnosis and treatment.

Summary:

• CMTD-2 shares prevalence with CMTD-1, but exhibits more severe muscle atrophy for equivalent weakness.
• Normal or minimally slowed nerve conduction velocities and reduced nerve potentials are characteristic, but not always present early, hindering presymptomatic diagnosis.
• Histopathology suggests primary motor and sensory neuron atrophy with secondary axonal degeneration.

Impact:

• Identifying genes within known loci and discovering new ones is the critical first step toward rapid molecular diagnosis of CMTD-2.
• This research paves the way for targeted genetic treatments for Type 2 Charcot-Marie-Tooth disease.
• Advances in understanding CMTD-2 genetics can improve diagnostic accuracy and patient management strategies.